SAREPTA THERAPEUTICS, INC. Deferred Tax Assets, Operating Loss Carryforwards
SAREPTA THERAPEUTICS, INC. (SRPT) had Deferred Tax Assets, Operating Loss Carryforwards of $96.59 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-02
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $96.59M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $67.59M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $154.95M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $241.83M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $96.59M 10-K · filed 2026-03-02 |
| 2024-12-31 | $67.59M 10-K · filed 2026-03-02 |
| 2023-12-31 | $154.95M 10-K · filed 2025-02-28 |
| 2022-12-31 | $241.83M 10-K · filed 2024-02-28 |
| 2021-12-31 | $330.39M 10-K · filed 2023-02-28 |
| 2020-12-31 | $333.70M 10-K · filed 2022-03-01 |
| 2019-12-31 | $304.03M 10-K · filed 2021-03-01 |
| 2018-12-31 | $212.34M 10-K · filed 2020-02-26 |
| 2017-12-31 | $144.90M 10-K · filed 2019-02-28 |
| 2016-12-31 | $174.57M 10-K · filed 2018-03-01 |
| 2015-12-31 | $138.79M 10-K · filed 2017-02-28 |
| 2014-12-31 | $115.70M 10-K · filed 2016-02-25 |
| 2013-12-31 | $94.17M 10-K · filed 2015-02-26 |
| 2012-12-31 | $85.60M 10-K · filed 2014-03-03 |
| 2011-12-31 | $87.27M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |